Published in Antimicrob Agents Chemother on April 01, 2006
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother (2006) 2.16
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother (2006) 1.81
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother (2008) 1.13
Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother (2006) 1.09
The chemical biology of new drugs in the development for tuberculosis. Curr Opin Chem Biol (2010) 1.03
A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis. Infect Dis Ther (2013) 0.86
The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob Agents Chemother (2009) 0.84
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis (2015) 0.84
Molecular assays for determining Mycobacterium leprae viability in tissues of experimentally infected mice. PLoS Negl Trop Dis (2013) 0.83
Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear. Infect Immun (2007) 0.79
An enlarged, adaptable active site in CYP164 family P450 enzymes, the sole P450 in Mycobacterium leprae. Antimicrob Agents Chemother (2011) 0.76
Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy. Risk Manag Healthc Policy (2016) 0.75
Resistance of M. leprae to quinolones: a question of relativity? PLoS Negl Trop Dis (2013) 0.75
Nitazoxanide is active against Mycobacterium leprae. PLoS One (2017) 0.75
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2004) 13.04
A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis (1968) 8.01
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature (2000) 7.66
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother (2005) 3.16
Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother (1999) 2.82
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother (2005) 2.74
THE EXPERIMENTAL DISEASE THAT FOLLOWS THE INJECTION OF HUMAN LEPROSY BACILLI INTO FOOT-PADS OF MICE. J Exp Med (1960) 2.03
Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. Int J Lepr Other Mycobact Dis (1982) 2.01
WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser (1998) 1.92
Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother (1996) 1.87
In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother (2003) 1.85
Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser (1982) 1.44
The "proportional bactericidal test": a method for assessing bactericidal activity in drugs against Mycobacterium leprae in mice. Lepr Rev (1978) 1.33
Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother (1996) 1.25
The effect of ultraviolet light radiation on Mycobacterium leprae. Int J Lepr Other Mycobact Dis (2000) 1.06
Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother (1998) 1.04
Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother (2000) 1.02
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2004) 13.04
The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med (2009) 5.78
Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med (2014) 4.95
The challenge of new drug discovery for tuberculosis. Nature (2011) 4.23
Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action. Antimicrob Resist Infect Control (2012) 3.02
Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol (2007) 2.83
TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol (2005) 2.70
Society's failure to protect a precious resource: antibiotics. Lancet (2011) 2.51
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother (2007) 2.50
Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother (2010) 2.34
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother (2006) 2.32
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem (2005) 2.31
Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol (2010) 2.26
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother (2006) 2.16
Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem (2008) 2.07
Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household members. Arch Intern Med (2009) 2.07
Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother (2002) 2.05
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.99
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother (2004) 1.96
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2012) 1.83
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother (2006) 1.81
Essentiality of FASII pathway for Staphylococcus aureus. Nature (2010) 1.77
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother (2003) 1.71
Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. J Clin Microbiol (2006) 1.71
In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother (2007) 1.68
Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob Agents Chemother (2008) 1.63
Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother (2008) 1.53
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J Med Chem (2005) 1.48
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) (2012) 1.47
[Nosocomial influenza outbreak in a geriatrics department: Effectiveness of preventive measures]. Presse Med (2006) 1.44
Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother (2006) 1.42
Rapid identification of mycobacterial whole cells in solid and liquid culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol (2010) 1.41
Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother (2006) 1.36
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother (2010) 1.36
Epidemiology of invasive methicillin-resistant Staphylococcus aureus clones collected in France in 2006 and 2007. J Clin Microbiol (2008) 1.35
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med (2009) 1.35
Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One (2010) 1.35
Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin. Antimicrob Agents Chemother (2006) 1.32
Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. J Clin Microbiol (2003) 1.31
Antibacterial resistance, Wayampis Amerindians, French Guyana. Emerg Infect Dis (2004) 1.30
Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother (2006) 1.29
Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.29
Structure of the imipenem-hydrolyzing class A beta-lactamase SME-1 from Serratia marcescens. Acta Crystallogr D Biol Crystallogr (2002) 1.29
Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis (2001) 1.29
Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med (2014) 1.27
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol (2012) 1.27
Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae. J Clin Microbiol (2011) 1.27
First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis. Biochem Biophys Res Commun (2006) 1.25
Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med (2011) 1.24
A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins (2007) 1.24
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem (2008) 1.21
Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother (2007) 1.19
Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One (2011) 1.18
French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992-2008: positive trends, but perseverance needed. Infect Control Hosp Epidemiol (2009) 1.17
Evaluation of the βLacta test, a rapid test detecting resistance to third-generation cephalosporins in clinical strains of Enterobacteriaceae. J Clin Microbiol (2013) 1.16
Phylogenetic distribution of CTX-M- and non-extended-spectrum-β-lactamase-producing Escherichia coli isolates: group B2 isolates, except clone ST131, rarely produce CTX-M enzymes. J Clin Microbiol (2012) 1.16
National multidrug-resistant bacteria (MDRB) surveillance in France through the RAISIN network: a 9 year experience. J Antimicrob Chemother (2012) 1.15
Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A (2009) 1.14
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother (2008) 1.13
Alignment of capsid protein VP1 sequences of all human rhinovirus prototype strains: conserved motifs and functional domains. J Gen Virol (2006) 1.12
Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study. J Hosp Infect (2002) 1.11
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med (2008) 1.11
Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother (2011) 1.11
New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother (2012) 1.10
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem (2005) 1.10
Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother (2012) 1.09
Patient's origin and lifestyle associated with CTX-M-producing Escherichia coli: a case-control-control study. PLoS One (2012) 1.07
Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother (2008) 1.06
An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents (2007) 1.05
Potential use of antiviral agents in polio eradication. Emerg Infect Dis (2008) 1.05
Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One (2011) 1.04
Extended-spectrum beta-lactamases in long-term-care facilities. Clin Microbiol Infect (2008) 1.04
Complete nucleotide sequence of the first KPC-2- and SHV-12-encoding IncX plasmid, pKpS90, from Klebsiella pneumoniae. Antimicrob Agents Chemother (2012) 1.03
DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 1.02
Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinb) (2010) 1.02
A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides. Antiviral Res (2006) 0.97
Endocarditis due to Neisseria bacilliformis in a patient with a bicuspid aortic valve. J Clin Microbiol (2009) 0.95
Outbreak of nontuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. J Clin Microbiol (2009) 0.95
The pentapeptide repeat proteins MfpAMt and QnrB4 exhibit opposite effects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone complex. J Bacteriol (2008) 0.95
ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob Agents Chemother (2009) 0.94
Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE). Antimicrob Resist Infect Control (2012) 0.94
On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data. J Comput Aided Mol Des (2003) 0.94
Characteristics of human intestinal Escherichia coli with changing environments. Environ Microbiol (2008) 0.93
Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin Infect Dis (2005) 0.93
The environmental pathogen Mycobacterium ulcerans grows in amphibian cells at low temperatures. Appl Environ Microbiol (2002) 0.93
Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J Clin Microbiol (2008) 0.93
Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res (2003) 0.92
Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009-2011. Sex Transm Infect (2013) 0.92